News
November 11, 2026
Beeline Medicines Announces Presentation of Phase 2 Results of Afimetoran in Systemic Lupus Erythematosus at ACR Convergence 2026
Read moreNovember 2, 2026
Beeline Medicines Initiates First Trial in Lupus Pivotal Development Program with Global Phase 2/3 DISCOVERY Trial of Afimetoran in Cutaneous Lupus Erythematosus (CLE)
Read moreOctober 27, 2026
Beeline Medicines to Present Results from the Phase 2 Trial of Afimetoran in Systemic Lupus Erythematosus as a Late-Breaking Oral Presentation at ACR Convergence 2026
Read moreSeptember 9, 2026
Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus
Read moreJune 30, 2026
Beeline Medicines Announces Upsized Series A of $426.3 Million to Advance Category-Leading Autoimmune and Inflammatory Disease Portfolio
Read moreApril 15, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases
Read moreJuly 28, 2025
